FIELD: medicine.
SUBSTANCE: invention relates to compounds which are inhibitors of MKK4 (mitogen-activated protein kinase 4), pharmaceutical compositions based thereon and use for enhancing liver regeneration and reducing or preventing hepatocyte death.
EFFECT: obtaining compounds which selectively inhibit protein kinase MKK4 relative to protein kinases JNK and MKK7 and can be used to enhance liver regeneration and reducing or preventing death of hepatocytes associated with selective inhibition of protein kinase MKK4 relative to protein kinase JNK and MKK7.
6 cl, 8 tbl, 243 ex
Title | Year | Author | Number |
---|---|---|---|
AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF | 2013 |
|
RU2607081C2 |
PYRAZOLE-SUBSTITUTED PYRIDINES WITH ANTICANCER ACTIVITY, THEIR USE AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2022 |
|
RU2823567C2 |
NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | 2013 |
|
RU2646754C2 |
Authors
Dates
2024-07-03—Published
2019-07-16—Filed